NanoBioFAB Secures $1.1M DHA SBIR Phase II contract for Revolutionary AI-Driven Nanosensor Technology in Pathogen Detection and Wound Infection Prediction Device

FREDERICK, Md., July 13, 2023 /PRNewswire-PRWeb/ -- NanoBioFAB, an innovative medical device company with advanced AI-driven nanosensor technology, is pleased to announce the receipt of a $1.1 million Defence Health Agency (DHA) SBIR Phase II contract for the research and development of the groundbreaking medical device designed for pathogen identification and wound infection prediction.